Podcasts about molecular

In today's episode, we explore the groundbreaking intersection of addiction, biology, and cancer with internationally recognized scientist Dr. Rafael Cuomo. Drawing on insights from his book Crave, Dr. Cuomo reveals how addiction is not simply a behavioral or psychological issue—it's a biological condition that reshapes the terrain of our health and directly contributes to the development of chronic disease, including cancer. Dr. Cuomo introduces the concept of “molecular scars”—long-term physiological changes left behind by repeated addictive behaviors, even low-grade ones like screen use or ultra-processed food consumption. He explains how these behaviors disrupt key systems in the body, including the dopamine, opioid, GABA, glutamate, cortisol, and the endocannabinoid systems, ultimately weakening immune surveillance, fueling inflammation, and accelerating cellular damage. From the anticipatory nature of craving to the role of trauma and adverse childhood experiences, this episode invites clinicians, patients, and everyday listeners to reconsider addiction not as a character flaw, but as a biologically driven imbalance with profound public health implications.

Before adjusting your thyroid meds, have you ever ruled out gut-based triggers?Gut imbalances can have a bigger impact on thyroid health than most realize, especially in autoimmune conditions like Graves' and Hashimoto's. When the gut barrier breaks down, the immune system can get confused and prevent symptoms from fully improving. Testing can also be tricky, and just because something shows up doesn't always mean it needs to be treated. In this episode, I walk through how I approach these situations; how to evaluate critically, when to dig deeper, and when the priority should be foundational support like stress, sleep, and diet.Tune in to get a clearer picture of how gut health could be influencing your thyroid!Episode Timeline: 00:00 – Introduction to the Question00:08 – How infections can impact gut and thyroid function01:15 – Molecular mimicry and immune confusion01:35 – Infections and overgrowths that may influence autoimmunity02:36 – Testing methods and treatment preferences03:39 – Parasite treatment debates and false negatives05:07 – Why root cause work goes beyond infection treatment06:03 – Episode Wrap up06:40 – Podcast OutroFree resources for your thyroid healthGet your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.comHigh-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Access hundreds of free articles at www.NaturalEndocrineSolutions.com Visit Dr. Eric's YouTube channel at www.youtube.com/c/NaturalThyroidDoctor/ To work with Dr. Eric, visit https://savemythyroid.com/work-with-dr-eric/

Are you a woman leader or entrepreneur considering a career pivot, especially from academia to the dynamic startup world? Do you wonder how to navigate this transition, build crucial relationships, and drive innovation in a new industry? This episode of How Women Inspire addresses these very challenges, offering invaluable insights into making a successful leap and fostering meaningful connections.This week's episode 177 of How Women Inspire Podcast is about transitioning from academia to startups! In this episode of How Women Inspire Podcast, Grace Wei is sharing the importance of building relationships and maintaining connections with experts and mentors. and actionable steps you can take right now to build a team culture at your startup. Grace Wei has held the position of COO at Encellin since 2016. Prior to that, Grace worked as a biologist at UCSF from 2005 to 2015. Grace Wei has a Bachelor's Degree in Human Genetics from McGill University and a Ph.D. in Molecular and Cellular Biology from the University of Chicago. Grace also completed programs at Stanford University Graduate School of Business and Y Combinator.Some of the talking points Julie and Grace go over in this episode include:Why building and maintaining strong relationships is paramount for founders and leadersThe unique benefits of different accelerators and how they can provide access to experts, community, and professional coaching for your startup journey.How transitioning from a specialized field like academia to a startup environment requires humility and a willingness to seek adviceThe importance of team culture for startup success, and how that differs from academia.What steps will you take today to cultivate your network and embrace new challenges?Thank you for listening! If you enjoyed this episode, take a screenshot of the episode to post in your stories and tag me!  And don't forget to follow, rate, and review the podcast and tell me your key takeaways!Learn more about How Women Inspire at https://www.howwomenlead.com/podcast CONNECT WITH GRACE WEI:LinkedInEncellinCONNECT WITH JULIE CASTRO ABRAMS:LinkedIn - JulieHow Women LeadHow Women InvestHow Women GiveInstagram - HWLLinkedIn - HWLFacebook - HWL

Two Women Inspiring Real Life with Stephanie Coxon and Kathy Anderson-Martin – Leaked memos suggest some want Robert F. Kennedy Jr. out as Secretary of Health & Human Services. Molecular biologist Dr. James Lyons-Weiler joins us to discuss who's behind this and why. We explore the trillion-dollar vaccine industry, informed consent, and the importance of critical thinking for your family's health...

Welcome back to today's Friday Review where I'll be breaking down the best of the week!     I'll be sharing specifics on these topics:     The Well-Lived Life (book review) Your First Lab Program (product review) “Molecular Jackhammers” & Cancer (research)     For all the details tune in to today's Cabral Concept 3444 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3444 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

Dr. Michelle Starz-Gaiano is Professor and Chair of Biological Sciences at the University of Maryland Baltimore County (UMBC). Michelle's research uses fruit flies to examine how cells in the body go to the right place at the right time. Understanding why and how cells use their genetic information to move through the body is critical because if this movement doesn't happen correctly, it could, for example, impact embryo development or affect how immune cells mobilize after an injury. Conversely, preventing cancer cells from moving could keep cancer from spreading to other parts of the body. Michelle often spends her free time cooking and baking. Her kitchen looks a little like a lab, and she enjoys experimenting with making different foods. Michelle and her family also like to spend time together, travel, and listen to music. She received her bachelor's degree in biology from the Massachusetts Institute of Technology and her PhD in Developmental Genetics from New York University. Afterwards, Michelle completed a postdoctoral fellowship at Johns Hopkins School of Medicine. She joined UMBC in 2008 and has received the Donald Creighton Outstanding Faculty Member Award from the UMBC Graduate Student Association for her excellent mentorship. In our interview, she shares more about her life and science.

JAZZENELAIRE EN VERANO.-16 FESTIVAL BAHIA JAZZ PUERTO DE SANTA MARIA.-JAZZACTUALIDAD.-MARTA SANCHEZ-PERPETUAL VOID Jueves 10 de julio THE MESSTHETICS AND JAMES BRANDON LEWIS JAMES BRADON LEWIS, saxo tenor. ANTHONY PIROG, guitarra. JOE LALLY, bajo. BRENDAN CANTY, batería. El carismático saxofonista y compositor James Brandon Lewis es el músico del momento en el amplio campo del jazz contemporáneo. Su debut "Molecular", que Lewis grabó con su cuarteto en 2020, solo unos meses antes del confinamiento, fue aclamado rotundamente como uno de los lanzamientos más emocionantes de ese año. Brandon Lewis es un activista de la música y un consagrado jazzman en constante búsqueda del desafío sonoro. The Messthetics son un trío instrumental que tiene en su formación a dos miembros de uno de los grupos que cambió el punk para siempre - Fugazi - ya que se abrieron a otros géneros y sobre todo a otras sensaciones. La banda tiene un sonido de jazz con actitud y sin prejuicios, con energía y tiempos de 4x4. Con Brandon Lewis han conformado el matrimonio perfecto, una amalgama de creatividades vívidas que se respetan y se quieren. Entre las referencias que afloran se escuchan ecos al ambiente que suele proponer Marc Ribot, o al espíritu de John Zorn. Viernes 11 de julio JIMMY WEINSTEIN'S TENOR QUARTET JIMMY WEINSTEIN, batería. CHRIS CHEEK, saxo tenor. MATT RENZI, saxo tenor. JAVIER DELGADO, contrabajo. La inusual instrumentación de este cuarteto, compuesto por dos saxos tenores, contrabajo y batería, surge de la idea de crear una formación que, al prescindir de un instrumento armónico, amplíe el espacio sonoro y otorgue mayor libertad a los solistas, sin perder la esencia de composiciones que han resistido la prueba del tiempo. El concepto detrás de esta propuesta es superponer este enfoque a un repertorio profundamente armónico, en el que resuenan melodías más antiguas y quizás menos conocidas. Estándares ya casi olvidados, como "I Won’t Dance" y "South of the Border", son ejemplos de piezas que encajan perfectamente con este cuarteto recién formado. La interacción entre la estructura y la espontaneidad crea una nueva perspectiva sobre melodías atemporales, logrando un equilibrio entre tradición e innovación. El grupo fue concebido por el baterista Jimmy Weinstein, cuya colaboración con los saxofonistas Chris Cheek y Matt Renzi se remonta a principios de la década de 1990, habiendo realizado una gran cantidad de giras y grabaciones a lo largo de los años. Weinstein también ha trabajado extensamente con el bajista Javier Delgado en varias formaciones, incluido su trío que realizó giras con la leyenda del jazz Sheila Jordan. Sábado 12 de julio MARC COPLAND PIANO SOLO MARC COPLAND, piano. Marc Copland es actualmente uno de los pianistas más valorados en el mundo del jazz por críticos y audiencia. Su estilo introspectivo y la innovadora generación de atmosferas hipnóticas, su recorrido por subgéneros varios, incluido el free jazz en sus comienzos, y su trayectoria de colaboración con músicos consagrados y también con nuevas promesas, lo convierten en un referente indispensable para aquellos adeptos de oído inquieto. El norteamericano, que empezó su carrera en el jazz como saxofonista, ha sido compañero de ruta de nombres de peso como John Abercrombie, Michael Brecker y Gary Peacok y entre sus influencias se encuentran Bill Evans y Hervie Hancock. Sus grabaciones en solo piano son exploraciones imprescindibles que incorporan elementos de música clásica, reflexiones literarias y un sofisticado trabajo de los espacios y los silencios. No se trata solo de un músico, sino de un pintor, un poeta, un narrador de historias sin palabras, capaz de cambiar la atmosfera de una sala con una balada y provocar un estado de trance en la audiencia. Marta Sánchez – Perpetual Void Marta Sánchez, pianista española afincada en Nueva York, debuta en Intakt Records con «Perpetual Void» un disco en el que le acompañan Savannah Harris a la batería y Chris Tordini en el contrabajo. Mucho más enérgico y abierto en las formas que en su anterior SAAM, en el que dominaba una personalísima introspección, aquí Sánchez busca el desarrollo último de las formas, de modo que se expanden desde temas más o menos abstractos a diálogos entre batería y contrabajo, piano y batería, contrabajo y piano, en frases que como apunta menciona Lauren du Graf en las notas del álbum, facilita que «la voz de Sánchez se destaque con claridad cinematográfica, con suficiente espacio para que interactúe con su sección rítmica, lo cual hace con libertad y sensibilidad». Como en gran parte de su producción musical, este «Perpetual Void» entra de lleno en el jazz de vanguardia, el del oído con cierto gusto por la ligera atonalidad de los caminos inexplorados, por ese casi salto al vacío que aquí de alguna manera se contiene…hasta el último momento. La voz de Marta Sánchez, compositora de los diez temas de este álbum, es de una elegancia sobrenatural como si estuviera por encima del propio acto de tocar en un aquí y un ahora, oscilando entre lo percursivo y lo etéreo sin esfuerzo y conectando con la sección rítmica sin pensar en «tener que hacerlo». En definitiva, un disco de piano que huye de lo obvio, pero también de la sofisticación cerebral «no matter what» destinada a unos pocos.

About Nagina Abdullah: Nagina Abdullah is a weight-loss coach for women in midlife and founder of the top-rated website MasalaBody.com. Nagina has a degree in Molecular and Cell Biology from UC Berkeley and earned an MBA at NYU. She has helped more than 1,500 women in midlife successfully lose weight permanently and create a lifestyle change. Nagina teaches women to boost their metabolism naturally to burn fat even when nothing else has worked. She focuses on adding and combining natural metabolism-boosting foods to reduce belly fat and get women unstuck so that they can live in their dream body.   What We Discuss In This Episode: The "Add, Don't Subtract" Method: How Eating More Helps Midlife Women Lose More Weight How to Debloat, Reduce Inflammation, & Burn Fat Naturally (Even After Menopause) How to Get Off Sugar with the 4-Part Fat-Burning Food Framework (While Still Enjoying Chocolate Cake!) How to Boost Metabolism to Lose Weight (Without Calorie Counting or Dieting) How to Boost Your Metabolism in Midlife by Adding, Timing, and Pairing Foods   Free Resource From Nagina Abdullah: Sweet Spice Cheat Sheet, which reveals the spice in your kitchen that helps curb sugar cravings and lower blood sugar—naturally. It includes: 3 powerful health benefits of this spice 5 simple ways to use it daily 1 easy recipe to get started

BUFFALO, NY – June 27, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.” In this study, researchers led by first authors Cleto Dantas Nogueira from the Federal University of Ceará and Argos Pathology Laboratory and Samuel Frota from Argos Pathology Laboratory, along with corresponding author Fabio Tavora from the previously mentioned institutions and Messejana Heart and Lung Hospital, investigated how HER2 gene mutations appear in cases of non-small cell lung cancer (NSCLC) in Northeastern Brazil. The team found that HER2 mutations showed significant genetic diversity and were often associated with other cancer-related genetic changes. These findings revealed diagnostic and treatment challenges in a population that is rarely studied, emphasizing the need for expanded access to molecular testing and targeted therapies. HER2 mutations are a known factor in several cancers, including breast and gastric cancers. In lung cancer—particularly NSCLC—these mutations are less common but remain clinically significant. Most existing research on HER2-mutated lung cancer focuses on high-income countries, leaving important gaps in knowledge about underrepresented regions such as Latin America. This study helps fill that gap by analyzing 13 patients with HER2-mutated NSCLC using clinical, pathological, and genomic data. The patients ranged in age from 34 to 82 years, and more than half were women. About half had never smoked. Their tumors often displayed complex genetic profiles, including additional mutations in genes such as TP53, KRAS, and STK11. The most common HER2 mutation identified was an insertion in exon 20, a known hotspot for activating mutations. “Trastuzumab deruxtecan (T-DXd) is the first HER2-targeted agent to show clinical efficacy in HER2-mutant non-small cell lung cancer (HER2m NSCLC).” Treatment strategies among the patients varied. Only one individual received HER2-targeted therapy. Most were treated with surgery, chemotherapy, immunotherapy, or a combination of these approaches. Outcomes also differed, with some patients surviving for years and others dying within months of diagnosis. These findings reinforce the need for early diagnosis and improved access to advanced treatments, particularly in low-resource settings. The study emphasizes the value of comprehensive molecular profiling in NSCLC. Because HER2 mutations often occur alongside other genetic alterations, full genomic analysis is crucial for guiding treatment decisions. Yet, such testing is not always available. The researchers propose a tiered diagnostic approach, beginning with basic screening and expanding to more advanced tests when necessary, to enhance patient care. This study provides valuable insights into the molecular characteristics of HER2-mutated NSCLC in a Brazilian population, highlighting the complexity and clinical relevance of these alterations. Larger studies are needed to clarify the prevalence and prognostic significance of HER2 mutations, as well as their impact on treatment response and survival. This knowledge is essential for advancing effective HER2-targeted therapies. The findings also support broader implementation of international clinical guidelines in Latin America and highlight the critical need to include underrepresented populations in cancer research. DOI - https://doi.org/10.18632/oncotarget.28737 Correspondence to - Fabio Tavora - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=hr5R9iDBFFI To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]

The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]

The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]

The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]

The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]

The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

In einer Großstadt zu leben, kann herausfordernd sein: viel Beton und wenig Grün, viel Lärm und wenig Ruhe. Auch hier können wir einen Weg finden, Achtsamkeit zu praktizieren, indem wir uns ein Umfeld erschaffen, das guttut. **********An dieser Stelle findet ihr die Übung:00:32:02 - Geleitete Meditation für mehr Achtsamkeit im Großstadtleben**********Quellen aus der Folge:Adli, M., & Schöndorf, J. (2020). Macht uns die Stadt krank? Wirkung von Stadtstress auf Emotionen, Verhalten und psychische Gesundheit. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz, 63, 979-968.Hunter, M. R., Gillespie, B. W., & Chen, S. Y. P. (2019). Urban nature experiences reduce stress in the context of daily life based on salivary biomarkers. Front Psychol 10: 722.Lederbogen, F., Kirsch, P., Haddad, L., Streit, F., Tost, H., Schuch, P., ... & Meyer-Lindenberg, A. (2011). City living and urban upbringing affect neural social stress processing in humans. Nature, 474(7352), 498-501. Olszewska-Guizzo, A., Sia, A., Fogel, A., & Ho, R. (2022). Features of urban green spaces associated with positive emotions, mindfulness and relaxation. Scientific reports, 12(1), 20695.Sudimac, S., Sale, V., & Kühn, S. (2022). How nature nurtures: Amygdala activity decreases as the result of a one-hour walk in nature. Molecular psychiatry, 27(11), 4446-4452.**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .**********Ihr habt Anregungen, Ideen, Themenwünsche? Dann schreibt uns gern unter achtsam@deutschlandfunknova.de

M

On This Week in HPC, Addison Snell and Doug Eadline prep for ISC25, take a look at Intersect360 Research's new forecast, and talk about the partnership between Meta and Berkeley Labs.

BUFFALO, NY – June 24, 2025 – A new precision #oncology paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.” In this report, led by Alberto Hernando-Calvo from Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology; Razelle Kurzrock from WIN Consortium and Medical College of Wisconsin; Oncotarget Editor-in-Chief Wafik S. El-Deiry from WIN Consortium and Legorreta Cancer Center at Brown University; and corresponding author Shai Magidi, also from WIN Consortium, along with colleagues, describe the case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. After analysis, the WIN International Molecular Tumor Board proposed different personalized treatment plans based on the tumor's unique genetic mutations. This case highlights the growing role of precision oncology in guiding therapies for patients with treatment-resistant cancers. Colorectal cancer is one of the deadliest cancers worldwide, and managing advanced cases remains a significant challenge. This patient had already received five prior treatment regimens, including chemotherapy and targeted therapies. Although some treatments were initially beneficial, the cancer eventually developed resistance. Molecular analysis revealed key mutations in genes such as BRAF, MET, APC, TP53, and NRAS, which are often linked to aggressive tumor behavior and reduced treatment effectiveness. With limited standard options left, the patient's case was presented and reviewed by the WIN International Molecular Tumor Board, a global panel of cancer experts. The team analyzed the clinical history and genetic profile to design new treatment approaches. These involved off-label drug combinations tailored to the specific mutations found in the tumor. For example, one approach combined trametinib, a drug that blocks cancer cell growth signals, with amivantamab, an antibody that attacks cancer-related proteins MET and EGFR, and regorafenib, which helps cut off blood supply to tumors and may counteract effects from APC and TP53 mutations. “Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily.” This case reflects a shift in cancer care from standardized protocols to precision approaches, where therapy is selected based on a tumor's molecular features. Such strategies aim to delay resistance and slow disease progression more effectively. The WIN International Molecular Tumor Board also discussed practical challenges, including access to medications, combining off-label drugs, and the difficulties of enrolling patients in clinical trials after multiple prior treatments. Although the ultimate treatment decision remained with the patient's physician, this report shows how international collaboration and precision oncology can expand options for patients facing limited alternatives. It also emphasizes the value of repeat genetic analysis during disease progression to monitor new mutations in the tumor that may impact treatment. While the patient ultimately died from cancer progression, this case serves as a model for how molecular analysis and expert input can be used to guide treatment even in complex and metastatic colorectal cancer. As personalized cancer strategies continue to evolve, they may offer potential pathways for patients who have exhausted standard treatment options. DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - shai.magidi@winconsortium.org Video short - https://www.youtube.com/watch?v=uWDtWNgpK7A To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

Drs Kaniksha Desai and Jennifer Sipos discuss molecular marker testing in the evaluation of thyroid nodules. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/index/list_15483_0

Imagine destroying cancer cells with nothing but a common hospital dye and a beam oflight. Researchers at Rice University have unveiled a revolutionary treatment that uses aspecial light to trigger violent vibrations in cancer cells, tearing them apart from the insidewith 99% efficiency in lab trials. Dubbed ‘molecular jackhammers,' this method couldspare millions from chemo's brutal side effects and target everything from melanoma tobreast cancer.Dr. Bob and Dr. Brockman take calls and emails from listeners

¿Qué pueden revelar los huesos sobre nuestras sociedades, desigualdades y memorias colectivas?En este episodio de La Hoja Suelta, conversamos con Daniela Sandoval, antropóloga física adscrita al Laboratorio de Genética Molecular de la Escuela Nacional de Antropología e Historia (ENAH).La antropología física también nos habla de la vida: de quiénes fuimos, qué comíamos, cómo enfermábamos, cómo moríamos… y cómo las estructuras sociales moldeaban nuestros cuerpos.¿Qué es realmente la antropología física?¿Qué papel juega la genética en la arqueología y en el estudio de la historia humana?¿Por qué sigue siendo una ciencia tan relevante hoy?Prepárate para una entrevista que une ciencia, ética, historia y cuerpo.Una conversación que mira al pasado… para entender el presente.

Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices

A afirmação do dia é: Eu vivo com presença e imagino com amor, minha experiência é sagrada e minha visão cria realidade. A meditação do Portal Alvorecer indicada para hoje é: Reestruturação Molecular dos Corpos Sutis. O cristal de conexão do dia é: Cristal branco. Links: Portal Alvorecer: portalalvorecer.com.br/ Gabi Rubi Store: loja.gabirubi.com.br/

Seth Diehl, our newest Ortho rep, joins me today to walk us through what makes the Ortho Molecular products exceptionally high quality and why they are our top choice. He explains how Ortho Molecular Products is the only remaining practitioner and supplement manufacturer and the only company that has not sold out. We also dive into our latest products, Choline Support, L-Theanine, Inositol Complex, Estro Support, Milk Thistle, and Neuro Support Magnesium. The benefits of combining L-Theanine with your morning coffee: It reduces the jittery caffeine excitement  It provides a relaxed energy boost It supports GABA, the most calming neurotransmitter Seth Diehl's Bio: Seth Diehl is an Account Executive with Ortho Molecular Products, proudly supporting healthcare practitioners throughout Iowa, including myself and the exceptional team at Integrative Health and Hormone Clinic.  Seth earned both his Bachelor's in Biology and Master's in Biomedical Sciences from Iowa State University. Initially unfamiliar with integrative and functional medicine, Seth quickly became an enthusiastic advocate after discovering the impactful role preventative approaches play in overall health.  Today, he combines his scientific expertise with a genuine passion for wellness, providing healthcare professionals with tailored health solutions and proactive patient care strategies. Seth feels privileged to collaborate with practitioners across his home state, backed by an organization that supports the transformation of the practice of medicine alongside integrative and functional medicine providers nationwide. In this episode: What differentiates Ortho Molecular Products from the rest, making them the best supplement manufacturer? How they use trademarked and patented raw materials throughout their product lines to ensure therapeutic outcomes Why you need to be careful when following the advice of influencers on social media- especially those with no background in healthcare  How Ortho Molecular Products safeguards its manufacturing processes by adhering to FDA regulations for its food and pharmaceutical products  How Choline Support supports cellular and mitochondrial membranes for better brain health and more energy How L-Theanine reduces stress and promotes relaxation without causing drowsiness How the unique form of magnesium in Neuro Magnesium Support improves sleep quality and memory and reduces brain fog How our new product, Inositol Complex, can be used to address the symptoms of PCOS How Estro Support helps women manage their menopause symptoms How Milk Thistle aids liver detoxification Links and Resources: Use code ENERGY to get 10% off ⁠⁠MITOCHONDRIAL COMPLEX Use code TURMERIC to get 10% off ⁠⁠TURMERIC Try Halo (Salt) Therapy for respiratory and skin health. Call 319-363-0033 to schedule your session. Relative Links for This Show: Neuro Magnesium Support  L-Theanine – 60 capsules Use code PODCAST for 10% off your next supplement purchase  Inositol Complex Choline Support EstroSupport Follow Your Longevity Blueprint  On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online   Follow Dr. Stephanie Gray  On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast

Stephen Wolfram answers questions from his viewers about the future of science and technology as part of an unscripted livestream series, also available on YouTube here: https://wolfr.am/youtube-sw-qaTopics discussed: The limits and future of software defined everything - Molecular design and biological engineering - Human enhancement and genome level modification

About Eric Betzig:Eric Betzig is a Professor of Molecular and Cell Biology at UC Berkeley, holding the Eugene D. Commins Presidential Chair in Experimental Physics. He is also a Senior Fellow at the Janelia Research Campus and an Investigator of the Howard Hughes Medical Institute. After earning his Ph.D. at Cornell and working at AT&T Bell Labs on near-field optics, he left academia in 1995 for the machine tool industry. He returned to science in 2005, building the first super-resolution single molecule localization microscope with Harald Hess, work that earned him the 2014 Nobel Prize in Chemistry. Today, he develops advanced microscopy techniques for biological discovery, including correlative super-resolution fluorescence and electron microscopy, and 4D dynamic imaging of living systems.About Gita Wirjawan:Gita is an Indonesian entrepreneur and educator. He is the founding partner of Ikhlas Capital and the chairman of Ancora Group. Currently, he is teaching at Stanford as a Visiting Scholar at the Shorenstein Asia-Pacific Research Center (APARC); and a fellow at the Harvard Kennedy School's Belfer Center for Science and International Affairs.Explore this episode and be part of our communityhttps://endgame.id/Collaborations and partnershipshttps://sgpp.me/contactus

An awe-inspiring journey into the world of proteins--how they shape life, and their remarkable potential to heal our bodies and our planet. Each fall, a robin begins the long trek north from Gibraltar to her summer home in Central Europe. Nestled deep in her optic nerve, a tiny protein turns a lone electron into a compass, allowing her to see north in colors we can only dream of perceiving. Taking us beyond the confines of our own experiences, The Color of North: The Molecular Language of Proteins and the Future of Life (Belknap Press, 2025) traverses the kingdom of life to uncover the myriad ways that proteins shape us and all organisms on the planet. Inside every cell, a tight-knit community of millions of proteins skillfully contorts into unique shapes to give fireflies their ghostly glow, enable the octopus to see predators with its skin, and make humans fall in love. Collectively, proteins orchestrate the intricate relationships within ecosystems and forge the trajectory of life. And yet, nature has exploited just a fraction of their immense potential. Shahir S. Rizk and Maggie M. Fink show how breathtaking advances in protein engineering are expanding on nature's repertoire, introducing proteins that can detect environmental pollutants, capture carbon dioxide from the atmosphere, and treat diseases from cancer to COVID-19. Weaving together themes of memory, migration, and family with cutting-edge research, The Color of North unveils a molecular world in which proteins are the pulsing heart of life. Ultimately, we gain a new appreciation for our intimate connections to the world around us and a deeper understanding of ourselves. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Sergio Perera is a chef & nutrition expert. Having trained as a professional chef in some of Spain's most respected restaurants and then training in Japan, a serendipitous moment saw Sergio become the go to private chef to Hollywood actors (such as Tom Cruise, Robert Downey Jr, Leonardo DiCaprio, Chris Hemsworth), athletes, royalty and politicians. Growing up in Spain he was naturally an advocate for the healthy Mediterranean diet, but it was working with actors which prompted him to study and learn more about nutrition and during his time with Chris Hemsworth he helped prepare him for the role Thor, optimising his nutrition to support his exercise and muscle building regime. He was an integral part of the successful training app known as CENTR by Chris Hemsworth, writing recipes, diet programs and meditations, offering subscribers a holistic wellness approach. Sergio has an international upbringing, born in Spain to a Mexican/American and Spanish Parents and growing up on a US Airforce base, has given Sergio a unique perspective on food and culture. Sergio's love for food and cooking began in his Grandfather's kitchen where he learnt the traditional cuisine of the Aragon region. At the age of 18, he set off to expand his repertoire of Spanish cuisine by training at some of the world's most prestigious restaurants such as ARZAK, Mugaritz and with Albert Adria at the iconic el Bulli restaurant in Roses, Spain. His curiosity and passion for culture eventually lead him to Kyoto, Japan where he was introduced to Kaiseki which is an exquisite form of dining that moves elegantly and poetically with the seasons.  Sergio has used his culinary and artistic experience to create beautiful and inspirational images for food books, magazines and film productions. He is currently the brand ambassador for Winning Appliances, working alongside John Winning's team on numerous culinary and creative projects. The most recent has been the opening of ORA Japanese dining and bar in Sydney's Waterloo. Always eager to embrace new opportunities, Sergio welcomes the chance to work with clients—whether they are actors preparing for a film, high-profile individuals seeking an exclusive private dinner, or those planning a special event. He has also trained numerous chefs in becoming the ultimate private chef/nutritionist for high profile families and individuals and has been creating a small team of elite chefs throughout Australia. He actively participates in restaurant consultations across Australia, Europe, and the U.S., ensuring that each culinary experience is tailored to meet the unique needs of his clients. We chat about his life changing time in Japan, intuition, mindfulness, living in his car, creativity and food, flow, Molecular gastronomy and working with the masters, the new chef, vulnerability, moving to Australia and working with Chris Hemsworth, love of music, fear, and of course food plus plenty more! Check Sergio out on: Instagram: https://www.instagram.com/sergio.perera Website: https://www.pererasergio.com/ ------------------------------------------- Follow @Funny in Failure on Instagram and Facebook https://www.instagram.com/funnyinfailure/ https://www.facebook.com/funnyinfailure/ and @Michael_Kahan on Insta & Twitter to keep up to date with the latest info. https://www.instagram.com/michael_kahan/ https://twitter.com/Michael_Kahan

An awe-inspiring journey into the world of proteins--how they shape life, and their remarkable potential to heal our bodies and our planet. Each fall, a robin begins the long trek north from Gibraltar to her summer home in Central Europe. Nestled deep in her optic nerve, a tiny protein turns a lone electron into a compass, allowing her to see north in colors we can only dream of perceiving. Taking us beyond the confines of our own experiences, The Color of North: The Molecular Language of Proteins and the Future of Life (Belknap Press, 2025) traverses the kingdom of life to uncover the myriad ways that proteins shape us and all organisms on the planet. Inside every cell, a tight-knit community of millions of proteins skillfully contorts into unique shapes to give fireflies their ghostly glow, enable the octopus to see predators with its skin, and make humans fall in love. Collectively, proteins orchestrate the intricate relationships within ecosystems and forge the trajectory of life. And yet, nature has exploited just a fraction of their immense potential. Shahir S. Rizk and Maggie M. Fink show how breathtaking advances in protein engineering are expanding on nature's repertoire, introducing proteins that can detect environmental pollutants, capture carbon dioxide from the atmosphere, and treat diseases from cancer to COVID-19. Weaving together themes of memory, migration, and family with cutting-edge research, The Color of North unveils a molecular world in which proteins are the pulsing heart of life. Ultimately, we gain a new appreciation for our intimate connections to the world around us and a deeper understanding of ourselves. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

An awe-inspiring journey into the world of proteins--how they shape life, and their remarkable potential to heal our bodies and our planet. Each fall, a robin begins the long trek north from Gibraltar to her summer home in Central Europe. Nestled deep in her optic nerve, a tiny protein turns a lone electron into a compass, allowing her to see north in colors we can only dream of perceiving. Taking us beyond the confines of our own experiences, The Color of North: The Molecular Language of Proteins and the Future of Life (Belknap Press, 2025) traverses the kingdom of life to uncover the myriad ways that proteins shape us and all organisms on the planet. Inside every cell, a tight-knit community of millions of proteins skillfully contorts into unique shapes to give fireflies their ghostly glow, enable the octopus to see predators with its skin, and make humans fall in love. Collectively, proteins orchestrate the intricate relationships within ecosystems and forge the trajectory of life. And yet, nature has exploited just a fraction of their immense potential. Shahir S. Rizk and Maggie M. Fink show how breathtaking advances in protein engineering are expanding on nature's repertoire, introducing proteins that can detect environmental pollutants, capture carbon dioxide from the atmosphere, and treat diseases from cancer to COVID-19. Weaving together themes of memory, migration, and family with cutting-edge research, The Color of North unveils a molecular world in which proteins are the pulsing heart of life. Ultimately, we gain a new appreciation for our intimate connections to the world around us and a deeper understanding of ourselves. Learn more about your ad choices. Visit megaphone.fm/adchoices

The creation of a landmark gene editing drug used to treat a baby with a rare genetic mutation which could help transform personalized medicine. Blood tests showed baby KJ had sky-high levels of ammonia, a toxic substance the body usually expels. The root cause was his genes - or more particularly a specific gene mutation. The race was on to try and treat him before his condition took a firm hold. His doctors came up with a radical solution - for the first time ever, they designed and applied a gene-editing drug in record time, specifically for him. Have we seen breakthrough in preventing genetic diseases? With Fyodor Urnov, a professor in the Molecular and Cell Biology Department at the University of California, Virginijus Šikšnys professor at the Life Science Center of Vilnius University, Waseem Qasim from the UCL Institute of Child Health in Great Ormond Street Hospital in London and Jennifer Doudna, Professor, University of California, Berkeley and founder of the Innovative Genomics Institute. Presented by Tanya Beckett. Produced by Bob Howard. Researched by Mauve Schaffer Edited by Tara McDermott.

In the second part of this special episode of Onc Now, Jonathan Sackier continues his thrilling conversation with Bradley Monk, a leading gynaecologic oncologist, with an in-depth discussion of the DUO-E trial, Monk's most impactful Society of Gynecologic Oncology (SGO) insights, and the integration of AI into the clinic. Timestamps:  00:00 – Introduction  00:40 – Quickfire questions  06:19 – Inspiration  08:31 – Molecular basis of cancer treatment  12:12 – DUO-E trial design  14:12 – Barriers to 4-drug regimen approval and access  20:01 – Most impactful SGO insights  21:10 – AI integration  24:03 – Three wishes  26:30 – Outro 

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support. What if your blood could reveal the future of your health - years before symptoms ever appear? In this episode of Eye on AI, Craig Smith sits down with Ash Anwar, co-founder of Molecular You, to explore how AI and advanced biomarker analysis are transforming how we detect and prevent disease.  From a real-life case where stage 1 pancreatic cancer was caught early, to the science behind tracking 250+ dynamic biomarkers, Ash breaks down how Molecular You is shifting healthcare from reactive treatment to proactive longevity.  They dive into the limitations of genetic testing, the power of machine learning models trained on clinical data, and how personalized action plans are helping individuals take control of their health in real time.  If you're curious about the intersection of AI, diagnostics, and the future of preventive medicine—this is a conversation you won't want to miss. Stay Updated: Craig Smith on X: https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) How AI Can Predict Disease Before It Happens   (02:02) Meet Ash Anwar: From Scientist to Health Tech Leader   (06:31) What Is Molecular You and How It Works   (09:43) Why Biomarker Tracking Over Time Is a Game-Changer   (15:46) How Molecular You Detected Stage 1 Pancreatic Cancer   (23:15) Biomarkers vs Genetics: What Really Matters   (28:11) The AI Models Behind Early Disease Detection   (32:37) How the Product Works for Clinics and Consumers   (35:05) Who They Compete With and What Makes Them Different   (37:34) Research vs Product: The Cancer Risk Challenge   (43:43) How Often Should You Get Tested?

La biofísica española Eva Nogales, catedrática de Biología Molecular en la Universidad de Berkeley, ha sido la primera española en ganar el Premio Shaw y suena en las quinielas para el Nobel, aunque no le guste demasiado oírlo. Es líder mundial en el estudio de la expresión genética y la fotografía atómica de las células. Está convencida de que conocer, átomo a átomo, de qué estamos hechos va a revolucionarlo todo: "este es nuestro siglo".

La biofísica española Eva Nogales, catedrática de Biología Molecular en la Universidad de Berkeley, ha sido la primera española en ganar el Premio Shaw y suena en las quinielas para el Nobel, aunque no le guste demasiado oírlo. Es líder mundial en el estudio de la expresión genética y la fotografía atómica de las células. Está convencida de que conocer, átomo a átomo, de qué estamos hechos va a revolucionarlo todo: "este es nuestro siglo".

Welcome to a brand new episode of Beyond the Thesis with Papa PhD! In this conversation, host David Mendes sits down with Dr. Colleen Kelly, a seasoned chemistry professor, researcher, and now award-winning author of children's chemistry comic books. With a PhD in chemistry from Penn State, Colleen's career has spanned environmental toxicology, medicinal chemistry, and decades of teaching at the University of Arizona. But it's her mission to transform “molecular literacy” for learners ages eight to one hundred and eight that sets her apart. Inspired by her own educational journey as a first-generation college student and by watching her students struggle with the basics of chemistry, Colleen shares how she's harnessing the power of stories and comics to make the foundational elements of science accessible—and fun—for kids (and adults!). In this episode, you'll hear about Colleen's personal path from student to researcher to educator, her realization that many students hit a wall due to “molecular illiteracy,” and her bold decision to bring chemistry alive through colorful storytelling. We'll explore how she draws on pop culture, imagination, and even comic book heroes to help students of all ages see and understand the science around them. You'll also get a peek at her Emmy-winning PBS documentary, Comic Book Chemistry, and her growing collection of educational comic adventures. Whether you're a scientist, an educator, a parent, or just someone who wants to see more people excited about science, this episode is packed with inspiration, practical insights, and heartwarming stories of curiosity, resilience, and the lifelong power of learning.   Creating fun and accessible chemistry stories has been a labor of love for Colleen as a retired University of Arizona chemistry professor and author of a series of kid's chemistry comic books. In 2023, the PBS short documentary, “Comic Book Chemistry” was awarded an Emmy. This documentary centered around Colleen's vision, chemistry comic book series and her success with teaching college-level chemistry concepts to kids. This vision was then presented as a TEDx talk, “Molecular Literacy for Ages 8 – 108” in 2025. During Colleen's 30 years of teaching chemistry, she became aware that her students were struggling with basic concepts, including fluency with the symbols for the elements themselves. These comic books, videos, and activities are Colleen's gift to all future scientists – one that will help them succeed in college chemistry. Colleen holds a Ph.D. in chemistry from Penn State University, was awarded a Chateaubriand Fellowship to conduct research at the Universite Pasteur in Strasbourg, France under the direction of Nobel Prize Winner, Jean-Marie Lehn. Colleen was a tenured faculty member with research expertise in environmental toxicology, medicinal chemistry, and chemistry education. She has published four chemistry textbooks, over 30 peer-reviewed articles, and has presented her work globally. What we covered in the interview:  Early Foundations Matter: Dr. Kelley argues for introducing the “alphabet of science” (the periodic table) to kids as young as 8, when their brains are wired to associate symbols with meaning – just like learning to read or play music.  Storytelling Changes Everything: By turning molecules into characters and chemistry lessons into narratives, students remember and see the science, rather than just memorize it.  Literacy Beyond Academics: Chemistry literacy empowers everyone, from future doctors to curious consumers, to make informed decisions about medicine, the environment, and everyday life. Science is a language everyone deserves to speak.  Whether you're eyeing your first job outside academia or aiming to grow within an organization, this episode has advice you can act on today! See the resources section below for Rob Lion's links! This episode's resources: Website: KidsChemicalSolutions.com Thank you, Colleen Kelley! If you enjoyed this conversation with Colleen, let her know by clicking the link below and leaving her a message on Linkedin: Send Colleen Kelley a thank you message on Linkedin! Click here to share your key take-away from this interview with David! Leave a review on Podchaser ! Support the show !   You might also like the following episodes: Sarah McLusky – Research Adjacent Podcast Collab Sara Thompson – Four Practices You Must Learn From Gig Workers Rayana Luna –Navigating Medical Affairs Careers Sylvie Lahaie – Navigating Stress and Anxiety in Graduate School

Steve Grzanich has the business news of the day with the Wintrust Business Minute. The University of Chicago has received a $21 million donation to establish a new quantum research center. Philanthropist Thea Berggren made the donation, and the new center will include her name. It’ll will be located in the Pritzker School of Molecular […]

Feel like your body's no longer responding the way it used to—despite doing everything “right”? In this episode, we're diving into the world of bioactive peptides: what they are, how they work, and why they're becoming a game changer for women over 35 dealing with fatigue, muscle loss, inflammation, and hormone shifts. We break down the science behind Make Wellness peptides and how they help your body heal, rebuild, and thrive from the inside out.   Hosted by Leanne Vogel.   Coaching and other supports available at: https://shop.healthfulpursuit.com/    Podcast Sponsors, links and offers available at: https://www.healthfulpursuit.com/podcast/  Bioactive Peptides: https://www.healthfulpursuit.com/make 

Artificial intelligence is reshaping our world – but what does that mean for healthcare, scientific discovery, and human potential? In Genesis: Artificial Intelligence, Hope, and the Human Spirit, co-authors Craig Mundie, Henry Kissinger, and Eric Schmidt explore the profound implications of AI on society. In this collaborative event between Town Hall Seattle and the Institute for Systems Biology (ISB), Craig Mundie joins Dr. Jim Heath, President of ISB, for a thought-provoking conversation about the future of AI. They will discuss insights from the book, the opportunities and challenges AI presents, and what it means for the way we live, work, and care for our health. Co-author, Genesis: Artificial Intelligence, Hope, and the Human Spirit, Craig Mundie is a leading technology executive and former Chief Research and Strategy Officer at Microsoft. Over his decades-long career, he has played a pivotal role in advancing artificial intelligence, computing, and national security initiatives. Alongside Henry Kissinger and Eric Schmidt, he co-authored Genesis, a deep exploration of AI's impact on society and the future of humanity. Mundie has served as an advisor to the U.S. government on technology policy and was a member of the President's Council of Advisors on Science and Technology. President and Professor, Institute for Systems Biology (ISB) Dr. Jim Heath is a pioneering scientist in systems biology, cancer research, and precision medicine. Since 2018, he has led ISB, driving interdisciplinary research in cancer and immune system dynamics while advancing innovative approaches to complex diseases. An internationally recognized scientist, Heath has received numerous honors, including the Irving Weinstein Award from the American Association for Cancer Research and the Sackler Prize in the Physical Sciences. Before ISB, he was the Elizabeth W. Gilloon Professor of Chemistry at Caltech and a Professor of Molecular and Medical Pharmacology at UCLA. Presented by Town Hall Seattle and Institute for Systems Biology. Buy the Book Genesis: Artificial Intelligence, Hope, and the Human Spirit Elliott Bay Book Company

Welcome to the podcast with Dr. Brendan McCarthy!   This episode takes you deep into the real-world practice of prescribing testosterone therapy for women. This is not a high-level overview—this is a nuts and bolts breakdown: ✅ Who it's for ✅ How it's dosed ✅ What labs to run ✅ What delivery methods are safest ✅ Why it's often done wrong—and how to get it right   With over 20 years of clinical experience, Dr. McCarthy shares the insights no seminar or textbook can offer, including the emotional and psychological challenges women face when beginning testosterone therapy, and the very real fears around side effects and community stigma.  

Garrett Butler, MD. Husband, father, son, friend, and family doc in rural WV. Undergraduate in Physics from Johns Hopkins University. Undergraduate in Molecular and Cell Biology from Towson University. MD from West Virginia University School of Medicine. Family Medicine residency at WVU SOM. Hospitalist at Vandalia Health Davis Medical Center. Outpatient family physician at Vandalia Health Broaddus Family Care. Hospitalist at Vandalia Health Broaddus Hospital. Medical director of Mansfield Place nursing home. Work With Us: Arétē by RAPID Health Optimization Links: Dr. Garrett Butler - Old Fellow Manor Anders Varner on Instagram Doug Larson on Instagram Coach Travis Mash on Instagram